Table 3.

Group differences in % change from previous timepoint including timepoints 1, 2, and 3 (main effects for the group).

	Free carnitine
Outcomes	Low level (< 25 μmol/L)	Normal level (≥ 25 μmol/L)	P-value
% Δ Number of seizures; mean ± SD
Baseline
Timepoint 1	−16.82 ± 96.56	−42.51 ± 41.63	0.1637
Timepoint 2	67.68 ± 117.22	−10.68 ± 45.32	0.0372
Timepoint 3	−20.82 ± 56.75	−18.81 ± 41.45	0.8801
% Δ BHB Levels; mean ± SD
Baseline
Timepoint 1	512.78 ± 269.93	371.13 ± 296.23	0.2221
Timepoint 2	−84.05 ± 2.97	50.33 ± 303.46	0.5064
Timepoint 3	208.67 ± 324.61	−10.72 ± 59.99	0.1746
% Δ Triglycerides; mean ± SD
Baseline
Timepoint 1	36.56 ± 82.81	−1.37 ± 48.59	0.0386
Timepoint 2	−30.96 ± 58.74	−4.86 ± 35.69	0.4920
Timepoint 3	15.21 ± 38.32	9.24 ± 42.65	0.8347
% Δ Body mass index; mean ± SD
Baseline
Timepoint 2	−6.18 ± 6.51	−5.55 ± 8.09	0.9734
Timepoint 2	−3.78 ± 2.94	−1.7 ± 5.7	0.6938
Timepoint 3	3.98 ± 9	1.84 ± 6.33	0.4624
# of ASM; mean ± SD
Baseline	1.73 ± 1.27	2.02 ± 0.82	0.5829
Timepoint 1	1.88 ± 1.09	1.89 ± 1.03	0.9544
Timepoint 2	1.25 ± 0.71	2.13 ± 0.99	0.1448
Timepoint 3	2 ± 0.71	1.88 ± 1.22	0.8593
% Seizure severity Δ; mean ± SD
Baseline
Timepoint 1	0.25 ± 0.45	0.18 ± 0.39	0.7024
Timepoint 2	0.25 ± 0.46	0.13 ± 0.34	0.5874
Timepoint 3	0 ± 0	0.18 ± 0.39	1.000

ASM, anti-seizure medication depicted as the number of medications prescribed as opposed to the percent change.

*P-values are derived from generalized mixed effect models.

Δ = change.